ASCO 2010 Gastrointenstinal

Article

American Society of Clinical Oncology 2010, GI Coverage

 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Related Content
Patients with BRAF fusion papillary thyroid cancer also had clinical benefit with the therapy.

How Does Plixorafenib Compare With Other BRAF-Mutant Thyroid Cancer Agents?

Tim Cortese
September 16th 2025
Article
Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 16th 2025
Podcast
Data from the IDeate-Lung01 trial support the potential role that ifinatamab deruxtecan may play in the management of extensive-stage small cell lung cancer.

I-DXd Shows “Impressive” Responses in Extensive-Stage SCLC

Russ Conroy
September 16th 2025
Article
A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 16th 2025
Podcast
The decision from the Ministry of Health, Labour, and Welfare was supported by phase 3 LUNAR trial results showing an OS benefit with Optune Lua in NSCLC.

TTFields Earns Japanese Approval in Unresectable Advanced/Recurrent NSCLC

Roman Fabbricatore
September 16th 2025
Article
Numerically higher ORRs were reported in those who received treatment in the second line vs third line, in those with a CTFI of 90 days or more, and those without CNS metastasis.

Lurbinectedin Yields Responses in Various ES-SCLC Subgroups

Tim Cortese
September 16th 2025
Article